NCT03163368
Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
StatusActive, Not Recruiting
PhaseEarly Phase 1
SponsorCedars-Sinai Medical Center
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 14 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 14 words
- Study completion pushed from Jun 1, 2026 to Sep 1, 2027
- Minor Study completion date: Nov 1, 2025 to Jun 1, 2026v17
- Minor Primary completion date changed from estimate of Dec 30, 2023 to Dec 15, 2022
- Study completion date: Jun 1, 2024 to Nov 1, 2025
- Notable Primary completion date: Dec 30, 2022 to Dec 30, 2023
- Study completion date: Jun 1, 2023 to Jun 1, 2024
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date: Dec 1, 2022 to Dec 30, 2022
- Site details revised
Show 8 earlier versionsHide 8 earlier versions
- Notable Primary completion date: Jun 1, 2022 to Dec 1, 2022
- Study completion date: Dec 1, 2022 to Jun 1, 2023
- Notable Primary completion date: Dec 1, 2021 to Jun 1, 2022
- Study completion date: Jun 1, 2022 to Dec 1, 2022
- Notable Primary completion date: Jun 1, 2021 to Dec 1, 2021
- Study completion date: Dec 1, 2021 to Jun 1, 2022
- Notable Primary completion date: Dec 1, 2020 to Jun 1, 2021
- Study completion date: Jun 1, 2021 to Dec 1, 2021
- Notable Primary completion date: Dec 1, 2019 to Dec 1, 2020
- Study completion date: Jun 1, 2020 to Jun 1, 2021
- Notable Eligibility criteria expanded, about 4 words
- Site contact updated
- Notable Primary completion date: Jan 1, 2019 to Dec 1, 2019
- Eligibility criteria expanded, about 4 words
- Study completion date: Jun 1, 2019 to Jun 1, 2020
- Site contact updated
- Notable Phase: Not applicable to Early Phase 1
- Eligibility criteria expanded, about 5 words
- Interventions: Neoadjuvant stereotactic radiosurgery (Radiation) to Neoadjuvant stereotactic radiosurgery (Radiation), Neurosurgical resection (Procedure)
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Maximum tolerated dose (MTD)
Timeframe: 1 month after neurosurgery
Secondary (7)
Adverse events
Describe preliminary rates of image-complete resection
Describe preliminary rates of local tumor control
Describe preliminary rates of intracranial control
Describe preliminary rates of progression-free survival
Show 2 moreShow less
Describe preliminary rates of leptomeningeal spread
Describe preliminary rates of rate of salvage treatment
Arms and interventions
Neoadjuvant stereotactic radiosurgeryExperimental
Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.
Radiation: Neoadjuvant stereotactic radiosurgery
Procedures: Neurosurgical resection
Sites
1 site in 1 country
- Cedars-Sinai Medical CenterLos Angeles, California, United States